Published in J Dtsch Dermatol Ges on July 01, 2003
[Atopic dermatitis guideline--no evidence based recommendations for phototherapy]. J Dtsch Dermatol Ges (2004) 0.75
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol (2000) 9.70
EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy (2009) 4.10
Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol (2004) 3.97
EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy (2009) 3.86
Nickel and molybdenum contact allergies in patients with coronary in-stent restenosis. Lancet (2000) 3.31
A novel non-viral vector for DNA delivery based on low molecular weight, branched polyethylenimine: effect of molecular weight on transfection efficiency and cytotoxicity. Pharm Res (1999) 3.19
The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy (2014) 3.10
A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med (1997) 2.29
Ultraviolet light depletes surface markers of Langerhans cells. J Invest Dermatol (1981) 2.28
Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol (2012) 2.17
Delayed-type hypersensitivity to low molecular weight heparins and heparinoids: cross-reactivity does not depend on molecular weight. Br J Dermatol (2007) 2.15
Sentinel node biopsy in melanoma delays recurrence but does not change melanoma-related survival: a retrospective analysis of 673 patients. Br J Dermatol (2005) 2.09
Prognostic significance of histopathological parameters in sentinel nodes of melanoma patients. Histopathology (2007) 2.02
ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther (2010) 1.83
Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. Allergy (2006) 1.80
Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol (2012) 1.77
Diagnosis of immediate allergic reactions to beta-lactam antibiotics. Allergy (2003) 1.69
Staphylococcus aureus: colonizing features and influence of an antibacterial treatment in adults with atopic dermatitis. Br J Dermatol (2002) 1.62
Antigen presentation by murine epidermal langerhans cells and its alteration by ultraviolet B light. J Immunol (1981) 1.60
EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy (2006) 1.55
Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. Br J Dermatol (2005) 1.54
Epidemiology of acne in the general population: the risk of smoking. Br J Dermatol (2001) 1.54
Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy (2014) 1.54
Early markers for protective mechanisms during rush venom immunotherapy. Allergy (2010) 1.50
Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. J Eur Acad Dermatol Venereol (2012) 1.49
Soluble E-selectin in sera of patients with atopic dermatitis and psoriasis--correlation with disease activity. Br J Dermatol (1996) 1.46
Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis. J Allergy Clin Immunol (2001) 1.45
Safety of rush insect venom immunotherapy. The results of a retrospective study in 178 patients. Allergy (2003) 1.44
Reducing the risk of anaphylaxis during anaesthesia: guidelines for clinical practice. J Investig Allergol Clin Immunol (2005) 1.43
Olive oil--contact sensitizer or irritant? Contact Dermatitis (1997) 1.41
Novel neutrophil chemotactic factor derived from human peripheral blood mononuclear leucocytes. Clin Exp Immunol (1986) 1.40
Leprosy type 1 reaction as the first manifestation of borderline lepromatous leprosy in a young native German. Br J Dermatol (1997) 1.39
Platitudes in allergy--based on the example of the euro. Contact Dermatitis (2001) 1.39
Putative association of a TLR9 promoter polymorphism with atopic eczema. Allergy (2007) 1.39
Topical mercury should be banned--dangerous, outmoded, but still popular. J Am Acad Dermatol (1991) 1.38
[SAPHO syndrome. Case description of 3 patients with acne conglobata and osteoarticular symptoms]. Hautarzt (1997) 1.38
Skin test concentrations for systemically administered drugs -- an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy (2013) 1.33
Reducing the risk of anaphylaxis during anesthesia: 2011 updated guidelines for clinical practice. J Investig Allergol Clin Immunol (2011) 1.31
New treatment modalities for granuloma faciale. Br J Dermatol (2003) 1.31
Immunomorphological and ultrastructural characterization of Langerhans cells and a novel, inflammatory dendritic epidermal cell (IDEC) population in lesional skin of atopic eczema. J Invest Dermatol (1996) 1.31
Langerhans cells as stimulator cells in the murine primary epidermal cell-lymphocyte reaction: alteration by UV-B irradiation. J Invest Dermatol (1982) 1.30
EAACI/GA2LEN/EDF guideline: management of urticaria. Allergy (2006) 1.28
Allergen specificity of skin-infiltrating T cells is not restricted to a type-2 cytokine pattern in chronic skin lesions of atopic dermatitis. J Invest Dermatol (1996) 1.24
Skin testing in patients with hypersensitivity reactions to iodinated contrast media - a European multicenter study. Allergy (2009) 1.24
Long term outcome of ocular adnexal lymphoma subtyped according to the REAL classification. Revised European and American Lymphoma. Br J Ophthalmol (2001) 1.23
Type I interferon-associated skin recruitment of CXCR3+ lymphocytes in dermatomyositis. Clin Exp Dermatol (2006) 1.22
Diagnostic tests based on human basophils: more potentials and perspectives than pitfalls. Int Arch Allergy Immunol (2008) 1.20
Important research questions in allergy and related diseases: nonallergic rhinitis: a GA2LEN paper. Allergy (2008) 1.20
Management of dermatofibrosarcoma protuberans with fibrosarcomatous transformation: an evidence-based review of the literature. J Eur Acad Dermatol Venereol (2011) 1.18
Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas. Br J Cancer (2008) 1.17
Benign symmetric lipomatosis Launois-Bensaude. Report of ten cases and review of the literature. J Am Acad Dermatol (1987) 1.17
Birch pollen-related foods trigger atopic dermatitis in patients with specific cutaneous T-cell responses to birch pollen antigens. J Allergy Clin Immunol (1999) 1.16
General considerations on rapid desensitization for drug hypersensitivity - a consensus statement. Allergy (2010) 1.16
Methods report on the development of the 2013 revision and update of the EAACI/GA2 LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria. Allergy (2014) 1.16
Diagnosis of nonimmediate reactions to beta-lactam antibiotics. Allergy (2004) 1.15
Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy (2005) 1.14
Distribution of Langerhans cells and mast cells within the human oral mucosa: new application sites of allergens in sublingual immunotherapy? Allergy (2008) 1.14
Detection of disease-specific restriction fragment length polymorphisms in pemphigus vulgaris linked to the DQw1 and DQw3 alleles of the HLA-D region. Proc Natl Acad Sci U S A (1987) 1.11
Identification of plectin in different human cell types and immunolocalization at epithelial basal cell surface membranes. Exp Cell Res (1984) 1.11
Increased IL-6 production by monocytes and keratinocytes in patients with psoriasis. J Invest Dermatol (1991) 1.10
The high-affinity IgE receptor (FcepsilonRI) blocks apoptosis in normal human monocytes. J Clin Invest (2000) 1.10
55-kd tumor necrosis factor receptor is expressed by human keratinocytes and plays a pivotal role in regulation of human keratinocyte ICAM-1 expression. J Invest Dermatol (1991) 1.10
Scarring skin lesions of discoid lupus erythematosus are characterized by high numbers of skin-homing cytotoxic lymphocytes associated with strong expression of the type I interferon-induced protein MxA. Br J Dermatol (2005) 1.10
Granulocyte-activating mediators (GRAM): I. Generation by lipopolysaccharide-stimulated mononuclear cells. J Invest Dermatol (1986) 1.09
Severe atopic dermatitis is associated with sensitization to staphylococcal enterotoxin B (SEB). Allergy (2000) 1.09
C5a suppresses the production of IL-12 by IFN-gamma-primed and lipopolysaccharide-challenged human monocytes. J Immunol (1999) 1.07
CD1 expression is not affected by human peptide transporter deficiency. Hum Immunol (1994) 1.07
C3a activates reactive oxygen radical species production and intracellular calcium transients in human eosinophils. Eur J Immunol (1994) 1.06
4beta-hydroxycholesterol as a marker of CYP3A4 inhibition in vivo - effects of itraconazole in man. Int J Clin Pharmacol Ther (2009) 1.05
Tumor necrosis factor beta and ultraviolet radiation are potent regulators of human keratinocyte ICAM-1 expression. J Invest Dermatol (1990) 1.05
C3a activates the respiratory burst in human polymorphonuclear neutrophilic leukocytes via pertussis toxin-sensitive G-proteins. Blood (1994) 1.05
Phorbol-12-myristate-13-acetate-treated human keratinocytes express B7-like molecules that serve a costimulatory role in T-cell activation. J Invest Dermatol (1993) 1.05
Activated human T lymphocytes express a functional C3a receptor. J Immunol (2000) 1.04
Modulation of human neutrophilic granulocyte functions by recombinant human tumor necrosis factor and recombinant human lymphotoxin. Promotion of adherence, inhibition of chemotactic migration and superoxide anion release from adherent cells. Clin Exp Immunol (1988) 1.04
Human eotaxin represents a potent activator of the respiratory burst of human eosinophils. Eur J Immunol (1996) 1.04
Immunological mechanisms of sublingual allergen-specific immunotherapy. Allergy (2011) 1.04
Sporotrichoid phaeohyphomycosis due to Alternaria infectoria. Br J Dermatol (2001) 1.04
Diagnostic tests based on human basophils: more potentials and perspectives than pitfalls. II. Technical issues. J Investig Allergol Clin Immunol (2008) 1.03
Evidence that singlet oxygen-induced human T helper cell apoptosis is the basic mechanism of ultraviolet-A radiation phototherapy. J Exp Med (1997) 1.02
Bacterial infections and atopic dermatitis. Allergy (2001) 1.02
[AWMF Guideline no. 013/066. Diagnosis and therapy of circumscribed scleroderma]. J Dtsch Dermatol Ges (2009) 1.02
High-dose UVA1 therapy in the treatment of patients with atopic dermatitis. J Am Acad Dermatol (1992) 1.02
Comparative analysis of nasal and oral mucosa dendritic cells. Allergy (2006) 1.02
The 55-kD tumor necrosis factor receptor on human keratinocytes is regulated by tumor necrosis factor-alpha and by ultraviolet B radiation. J Clin Invest (1993) 1.01
Analysis of the high affinity IgE receptor genes reveals epistatic effects of FCER1A variants on eczema risk. Allergy (2009) 1.01
Late eczematous reactions to food in children with atopic dermatitis. Clin Exp Allergy (2004) 1.01
Characterization and topography of the glycoproteins of adrenal chromaffin granules. J Neurochem (1979) 1.01
Colonoscopic allergen provocation (COLAP): a new diagnostic approach for gastrointestinal food allergy. Gut (1997) 1.01
Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils. Blood (1996) 1.01
Circulating levels of brain-derived neurotrophic factor correlate with disease severity in the intrinsic type of atopic dermatitis. Allergy (2006) 0.99
Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy (2008) 0.99
The expression pattern of interferon-inducible proteins reflects the characteristic histological distribution of infiltrating immune cells in different cutaneous lupus erythematosus subsets. Br J Dermatol (2007) 0.99
Human eosinophils produce biologically active IL-12: implications for control of T cell responses. J Immunol (1998) 0.99
Anaphylactic shock following peritumoral injection of patent blue in sentinel lymph node biopsy procedure. Eur J Surg Oncol (2000) 0.98
Tissue eosinophilia in acute and chronic atopic dermatitis: a morphometric approach using quantitative image analysis of immunostaining. Br J Dermatol (2001) 0.98